APP and Alzheimer disease: In this category, prior to the activation of the AβPP-independent iAβ production pathway, the long-term anti-inflammatory therapy would protect from the onset of AD (by precluding the elicitation of the ISR and, consequently, of the AβPP-independent iAβ production pathway), whereas after the commencement of AD, the implementation of the transient iAβ depletion via its targeted degradation would be effective if it is paralleled by the long-term anti-inflammatory therapy.